Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Sep 10;28(14):2061-70.
doi: 10.1097/QAD.0000000000000360.

2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque

Markella V Zanni  1 , Kathleen V Fitch, Meghan Feldpausch, Allison Han, Hang Lee, Michael T Lu, Suhny Abbara, Heather Ribaudo, Pamela S Douglas, Udo Hoffmann, Janet Lo, Steven K Grinspoon
Affiliations
Comparative Study

2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque

Markella V Zanni et al. AIDS. .

Abstract

Background: The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines are being applied to HIV-infected patients but have not been validated in this at-risk population, which is known to have a high prevalence of subclinical high-risk morphology (HRM) coronary atherosclerotic plaque.

Objective: To compare recommendations for statins among HIV-infected subjects with/without HRM coronary plaque according to 2013 ACC/AHA versus 2004 Adult Treatment Panel III guidelines.

Methods/design: Data from 108 HIV-infected subjects without known cardiovascular disease (CVD) or lipid-lowering treatment who underwent contrast-enhanced computed tomography angiography were analyzed. Recommendations for statin therapy according to 2013 versus 2004 guidelines were assessed among those with/without HRM coronary plaque.

Results: Among all subjects, 10-year atherosclerotic cardiovascular disease (ASCVD) risk score was 3.3% (1.6, 6.6), yet 36% of subjects had HRM coronary plaque. Among those with HRM coronary plaque, statins would be recommended for 26% by 2013 guidelines versus 10% by 2004 guidelines (P = 0.04). Conversely, among those without HRM coronary plaque, statins would be recommended for 19% by 2013 guidelines versus 7% by 2004 guidelines (P = 0.005). In multivariate modeling, while 10-year ASCVD risk score related to HRM coronary plaque burden (P = 0.02), so too did other factors not incorporated into 2013 guidelines.

Conclusion: The 2013 ACC/AHA cholesterol guidelines recommend statin therapy for a higher percentage of subjects with and without HRM coronary plaque relative to 2004 guidelines. However, even by 2013 guidelines, statin therapy would not be recommended for the majority (74%) of HIV-infected subjects with subclinical HRM coronary plaque. Outcome studies are needed to determine the utility of new statin recommendations and the contribution of HRM coronary plaque to CVD events among HIV-infected subjects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 1a. Percentage of Subjects with and without Subclinical Coronary Atherosclerotic Plaque for whom Statins Would be Recommended according to 2013 ACC/AHA Guidelines versus 2004 ATP III Guidelines Figure 1b. Percentage of Subjects with and without Subclinical High Risk Morphology Coronary Atherosclerotic Plaque for whom Statins Would be Recommended according to 2013 ACC/AHA Guidelines versus 2004 ATP III Guidelines
Figure 1
Figure 1
Figure 1a. Percentage of Subjects with and without Subclinical Coronary Atherosclerotic Plaque for whom Statins Would be Recommended according to 2013 ACC/AHA Guidelines versus 2004 ATP III Guidelines Figure 1b. Percentage of Subjects with and without Subclinical High Risk Morphology Coronary Atherosclerotic Plaque for whom Statins Would be Recommended according to 2013 ACC/AHA Guidelines versus 2004 ATP III Guidelines
See this image and copyright information in PMC

Comment in

References

    1. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 - PubMed
    1. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239. - PubMed
    1. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis. 2012;205(Suppl 3):S375–382. - PMC - PubMed
    1. Zanni MV, Grinspoon SK. HIV-specific immune dysregulation and atherosclerosis. Curr HIV/AIDS Rep. 2012;9:200–205. - PubMed
    1. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, et al. HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol. 2013;61:511–523. - PubMed

Publication types

MeSH terms

Substances